JenaValve Technology, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From JenaValve Technology, Inc.
ANI pharma strengthens leadership team by adding three new executives to accelerate future growth. While Coherus and Xbrane appoint new chief financial officers, Lupin and Beximco hire new independent directors. Sandoz is certified “Global Top Employer 2021” yet again by Top Employers Institute.
Value-added medicines specialist Hyloris has struck a deal worth up to €4.3m with Purna Female Healthcare to develop a treatment for vulvovaginal candidiasis that combines miconazole and domiphen bromide.
Belgian value-added medicines specialist Hyloris Pharmaceuticals has bolstered its management team with the appointment of a chief operating officer, shortly after receiving eight European approvals for its Maxigesic IV pain treatment.
With the main aim of developing its existing product portfolio and pursuing business development opportunities in the US, Hyloris Pharmaceuticals has successfully raised €80m through a public listing. The company has announced its financial results for the first half of 2020.
- Implantable Devices
Surgical Equipment & Devices
- Minimally or Less Invasive
- Other Names / Subsidiaries
- JenaValve Technology GmbH